Prognosis of Spontaneous Pneumothorax/Pneumomediastinum in Coronavirus Disease 2019 : The CoBiF Score
Objectives: Pneumothorax and pneumomediastinum are associated with high mortality in invasively ventilated coronavirus disease 2019 (COVID-19) patients; however, the mortality rates among non-intubated patients remain unknown. We aimed to analyze the clinical features of COVID-19-associated pneumothorax/pneumomediastinum in non-intubated patients and identify risk factors for mortality. Methods: We searched PubMed Scopus and Embase from January 2020 to December 2021. We performed a pooled analysis of 151 patients with no invasive mechanical ventilation history from 17 case series and 87 case reports. Subsequently, we developed a novel scoring system to predict in-hospital mortality; the system was further validated in multinational cohorts from ten countries (n = 133). Results: Clinical scenarios included pneumothorax/pneumomediastinum at presentation (n = 68), pneumothorax/pneumomediastinum onset during hospitalization (n = 65), and pneumothorax/pneumomediastinum development after recent COVID-19 treatment (n = 18). Significant differences were not observed in clinical outcomes between patients with pneumomediastinum and pneumothorax (±pneumomediastinum). The overall mortality rate of pneumothorax/pneumomediastinum was 23.2%. Risk factor analysis revealed that comorbidities bilateral pneumothorax and fever at pneumothorax/pneumomediastinum presentation were predictors for mortality. In the new scoring system, i.e., the CoBiF system, the area under the curve which was used to assess the predictability of mortality was 0.887. External validation results were also promising (area under the curve: 0.709). Conclusions: The presence of comorbidity bilateral pneumothorax and fever on presentation are significantly associated with poor prognosis in COVID-19 patients with spontaneous pneumothorax/pneumomediastinum. The CoBiF score can predict mortality in clinical settings as well as simplify the identification and appropriate management of patients at high risk.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 11(2022), 23 vom: 30. Nov. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Coronavirus disease |
|---|
| Anmerkungen: |
Date Revised 06.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm11237132 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350109168 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350109168 | ||
| 003 | DE-627 | ||
| 005 | 20231226044219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11237132 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM350109168 | ||
| 035 | |a (NLM)36498706 | ||
| 035 | |a (PII)7132 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Woo, Wongi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognosis of Spontaneous Pneumothorax/Pneumomediastinum in Coronavirus Disease 2019 |b The CoBiF Score |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Objectives: Pneumothorax and pneumomediastinum are associated with high mortality in invasively ventilated coronavirus disease 2019 (COVID-19) patients; however, the mortality rates among non-intubated patients remain unknown. We aimed to analyze the clinical features of COVID-19-associated pneumothorax/pneumomediastinum in non-intubated patients and identify risk factors for mortality. Methods: We searched PubMed Scopus and Embase from January 2020 to December 2021. We performed a pooled analysis of 151 patients with no invasive mechanical ventilation history from 17 case series and 87 case reports. Subsequently, we developed a novel scoring system to predict in-hospital mortality; the system was further validated in multinational cohorts from ten countries (n = 133). Results: Clinical scenarios included pneumothorax/pneumomediastinum at presentation (n = 68), pneumothorax/pneumomediastinum onset during hospitalization (n = 65), and pneumothorax/pneumomediastinum development after recent COVID-19 treatment (n = 18). Significant differences were not observed in clinical outcomes between patients with pneumomediastinum and pneumothorax (±pneumomediastinum). The overall mortality rate of pneumothorax/pneumomediastinum was 23.2%. Risk factor analysis revealed that comorbidities bilateral pneumothorax and fever at pneumothorax/pneumomediastinum presentation were predictors for mortality. In the new scoring system, i.e., the CoBiF system, the area under the curve which was used to assess the predictability of mortality was 0.887. External validation results were also promising (area under the curve: 0.709). Conclusions: The presence of comorbidity bilateral pneumothorax and fever on presentation are significantly associated with poor prognosis in COVID-19 patients with spontaneous pneumothorax/pneumomediastinum. The CoBiF score can predict mortality in clinical settings as well as simplify the identification and appropriate management of patients at high risk | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a coronavirus disease 2019 | |
| 650 | 4 | |a pneumomediastinum | |
| 650 | 4 | |a pneumothorax | |
| 650 | 4 | |a prediction model | |
| 700 | 1 | |a Kipkorir, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Marza, Adina Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Hamouri, Shadi |e verfasserin |4 aut | |
| 700 | 1 | |a Albawaih, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Dhali, Arkadeep |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Wooshik |e verfasserin |4 aut | |
| 700 | 1 | |a Udwadia, Zarir F |e verfasserin |4 aut | |
| 700 | 1 | |a Nashwan, Abdulqadir J |e verfasserin |4 aut | |
| 700 | 1 | |a Shaikh, Nissar |e verfasserin |4 aut | |
| 700 | 1 | |a Belletti, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Landoni, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Palumbo, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Swed, Sarya |e verfasserin |4 aut | |
| 700 | 1 | |a Sawaf, Bisher |e verfasserin |4 aut | |
| 700 | 1 | |a Buonsenso, Danilo |e verfasserin |4 aut | |
| 700 | 1 | |a Pimenta, Inês |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, Filipe André |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorentino, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Rashid Ali, Muhammad Redzwan S |e verfasserin |4 aut | |
| 700 | 1 | |a Quincho-Lopez, Alvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Javanbakht, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Alhakeem, Ayat |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Muhammad Mohsin |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Sangam |e verfasserin |4 aut | |
| 700 | 1 | |a Rafiee, Moezedin Javad |e verfasserin |4 aut | |
| 700 | 1 | |a Padala, Sri Rama Ananta Nagabhushanam |e verfasserin |4 aut | |
| 700 | 1 | |a Diebel, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Seung Hwan |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Du-Young |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Duk Hwan |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hye Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Juyeon |e verfasserin |4 aut | |
| 700 | 1 | |a Flower, Luke |e verfasserin |4 aut | |
| 700 | 1 | |a Yon, Dong Keon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Seung Won |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Jae Il |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sungsoo |e verfasserin |4 aut | |
| 700 | 1 | |a International Covid-Pneumothorax Working Group Icp-Wg |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 11(2022), 23 vom: 30. Nov. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:23 |g day:30 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm11237132 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 23 |b 30 |c 11 | ||